Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Voriconazole shows a considerable interpatient variation of serum concentrations. METHODS AND RESULT: In an analysis of 28 treatment courses, 6 patients presented with neurological adverse events (hallucination, encephalopathy, and visual disturbance). The hazard ratio per 0.1 mg/mL voriconazole serum level (sVL) increase was 2.27 (95% CI: 1.45-3.56, p <0.001). There was no correlation between sVL and creatinine (r = 0.12, p = 0.114), ALT (r = -0.14, p = 0.072), AST (r = 0.003, p = 0.964), alkaline phosphatase (r = 0.03, p = 0.723). CONCLUSIONS: Our findings demonstrate that elevated sVL is associated with neurological adverse events, and measurement of its serum concentration could improve voriconazole treatment and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
“1 mg/L increase in voriconazole trough level [14].”
BackgroundResultAshbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Metadata
- Authors
- Imhof, A., J. Schaer, D., Schwarz, U., & Schanz, U.
- Venue
- Swiss Medical Weekly
- Publisher
- SMW Supporting Association
- Published
- 2006-11-18
- Volume
- 136
- Issue
- 4546
- Pages
- 739-742
- ISSN
- 0036-7672 (ISSN-L)
- 1424-3997
- OpenAlex
- W38637850
- Cited by
- 151
- References
- 2
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. https://app.cochat.ai/papers/10.4414/smw.2006.11547
- The paper
- Imhof, A., J. Schaer, D., Schwarz, U., & Schanz, U. (2006). Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Medical Weekly. https://doi.org/10.4414/smw.2006.11547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.